TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06531304

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lokomat Robot Assisted Gait Training
Description: Patients will underwent 12 RAGT training sessions (3 times/week for 4 consecutive weeks, 45 min each including the time for wearing the harness and the exoskeleton) with the Lokomat device as add-on to conventional regimen (5 times/week, 80 min each). The Lokomat is a technologically advanced robot-assisted gait training device. Patients are supported in a harness above a treadmill while the robotic device assists the movements of their legs to provide physiological gait. As treatment progresses, weight bearing is increased and assistance from the robotic legs is reduced, requiring the patient to gradually assume greater responsibility for movements needed during walking.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat Robot Assisted Gait Training
Description: Patients will underwent 12 RAGT training sessions (3 times/week for 4 consecutive weeks, 45 min each including the time for wearing the harness and the exoskeleton) with the Lokomat device as add-on to conventional regimen (5 times/week, 80 min each). The Lokomat is a technologically advanced robot-assisted gait training device. Patients are supported in a harness above a treadmill while the robotic device assists the movements of their legs to provide physiological gait. As treatment progresses, weight bearing is increased and assistance from the robotic legs is reduced, requiring the patient to gradually assume greater responsibility for movements needed during walking.
Study: NCT06485011

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Without Platysma suturing
Description: platysma muscle was not sutured in this group
Study: NCT06524895

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Reiki
Description: Reiki is a form of energy therapy involving the facilitation of healing through the manipulation of biofields utilizing light touch. It is a process of targeting the energy fields around the patient's body is believed to stimulate the patient's natural ability to heal itself.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Reiki
Description: Sham Reiki involves a non-Reiki healer who mimics the treatment of a Reiki healer. Sham Reiki providers will be medical students who are not interested and without prior knowledge or experience with Reiki Medicine.The medical students will not have any prior experience in Reiki healing or associated energy healing modalities. It is better for this project if the medical student has no interest so there is true placebo effect being monitored.
Study: NCT05370729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: Intravenous infusion of NAC 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.
Study: NCT05805839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-11 ER176 Radiotracer
Description: Administered at a single time IV prior to the PET imaging. The injected dose of C-11 ER176 will be 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-11 ER176 Radiotracer
Description: Administered at a single time IV prior to the PET imaging. The injected dose of C-11 ER176 will be 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C11 Pittsburgh Compound B
Description: Administered at a single time IV prior to the PET imaging. The injected dose of C-11 PiB will be 555 MBq (range 370 - 629 MBq).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C11 Pittsburgh Compound B
Description: Administered at a single time IV prior to the PET imaging. The injected dose of C-11 PiB will be 555 MBq (range 370 - 629 MBq).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: Imaging of entire brain

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: Imaging of entire brain

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic Resonance Imaging of the Brain

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic Resonance Imaging of the Brain
Study: NCT06183242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remaxa, enteric-coated tablets
Description: enteric-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remaxa, enteric-coated tablets
Description: enteric-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remaxa, enteric-coated tablets
Description: enteric-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remaxa, enteric-coated tablets
Description: enteric-coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remaxol
Description: solution for infusions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remaxol
Description: solution for infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: enteric-coated tablets
Study: NCT04817605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations.To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.
Study: NCT04974723

Intervention type: DRUG
Intervention: Abaloparatide
Description: Abaloparatide subcutaneous (abaloparatide SC \[ABL\]; Tymlos®)

Intervention type: DRUG
Intervention: Teriparatide
Description: Teriparatide subcutaneous (TPTD; Forteo®)
Study: NCT05399368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPT193
Description: RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPT193
Description: RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPT193
Description: RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nonactive placebo tablet
Study: NCT04657601

Intervention type: DEVICE
Intervention: DiLumen C2 Endolumenal Interventional Platform
Description: Dual balloon accessory to an endoscope and related instruments
Study: NCT05969678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breathing training
Description: receive the breathing training of abdominal diaphragmatic breathing method combined with incentive spiromete
Study: NCT05289219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXPOBAR
Description: Each session will start with 5 minutes of warm-up and finalization with 10 minutes of a cool-down, with work of flexibility and proprioception. The maintenance of balance and postural stability may be compromised in obese individuals, depending on the degree of obesity, although the support base provided by the position of the foot is proportional to the structural morphology of each subject. Flexibility is also gradually impaired in obese individuals and of course, these changes may be related to postural changes aggravated by a sedentary lifestyle and biological aging itself alongside all metabolic alterations inherent to the pathology of obesity (Benetti et al., 2016). And the warm-up and the cool-down will be developed as the component of training with the evolution by phases, both in time and in intensity. The first phase will include 20 minutes of interval training, encompassing circuit strength training. Each phase will have an increment of 10 minutes in the central block.
Study: NCT05247008

Intervention type: OTHER
Group type: OTHER
Intervention: Thyme honey
Description: * Thyme honey will topically be applied to the oral mucosa as oral rinse based on the Biswal et al. (2003) administration protocol.~* Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day.
Study: NCT05057858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-formulated 300 mg TDF/ 200mg FTC
Description: Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 300 mg TDF/ 200mg FTC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-formulated 300 mg TDF/ 200mg FTC
Description: Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 300 mg TDF/ 200mg FTC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-formulated 300 mg TDF/ 200mg FTC
Description: Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 300 mg TDF/ 200mg FTC
Study: NCT06319560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Oral Tablet
Description: 200mg daily
Study: NCT06511271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: relaxation exercises
Description: The first 10-minute part of the CD audio recordings prepared by the Turkish Psychologists Association is about deep relaxation.~purpose; The second 30-minute part includes instructions for relaxation exercises; The last 30 minutes are just consists of relaxation music
Study: NCT05746767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported dCBT
Description: In the supported dCBT condition, each patient will receive complete access to the SilverCloud platform. In addition, patients will be assigned a supporter who will provide regular support based on an established coaching support protocol. Supporters will conduct a brief engagement call (30-40 minutes) to provide an overview of SilverCloud, identify goals, and set expectations, introduce themselves, and orient the participant to the role of the peer supporter. Supporters will then provide weekly check-ins through phone calls or messaging. Participants will be able to communicate with the supporters through the platform through messaging or sharing activities for additional discussion. The major goal of the support is to promote use of the platform.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unsupported dCBT
Description: Unsupported dCBT provides all features of the SilverCloud platform with the exception of support features (structured interactions with supporter and share features). Patients will be provided complete access to SilverCloud and instructed to use it for 8-weeks. Patients will receive weekly automated messages to encourage engagement.
Study: NCT05460078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Psychiatric Transition of Care Program
Description: Behavioral Health facility or units that have discharged patients meeting inclusion criteria will be randomly assigned as either an intervention or standard care site. Intervention sites will be those using the VPTC program. This evaluation design will integrate into current workflows for the measurement of outcomes. Prior to discharge, patients may be referred to the VPTC program if they report residency or shelter in North Carolina, are 18 years of age or older on the day of discharge and can access virtual care (phone/video).~The VPTC program is defined by:~* Psychiatric consultation~* Medication management services with pharmacological consultation~* following of Health Coaching participation and provide treatment recommendations~* Tracking of behavioral health symptoms and provide treatment recommendations~* Health coaching; Psychoeducational support~* Treatment and safety planning~* Assistance connecting with an outpatient care provider
Study: NCT05071313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF-based vaccine
Description: Ad26.RSV.preF-based vaccine will be administered as single IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF-based vaccine
Description: Ad26.RSV.preF-based vaccine will be administered as single IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent High-dose Influenza Vaccine
Description: Quadrivalent High-dose Influenza Vaccine will be administered as IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent High-dose Influenza Vaccine
Description: Quadrivalent High-dose Influenza Vaccine will be administered as IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as IM injection to Ad26.RSV.preF-based vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as IM injection to Ad26.RSV.preF-based vaccine.
Study: NCT06544681

Intervention type: PROCEDURE
Intervention: Coronary stenting with planned drug eluting stent (DES).
Description: Stenting will be performed with OCT guidance according to the algorithm described in the protocol. A deep learning-based OCT system was used to measure the adherence of coronary stents.

Intervention type: PROCEDURE
Intervention: Coronary stenting with planned drug eluting stent (DES).
Description: Stenting will be performed with OCT guidance according to the algorithm described in the protocol. A deep learning-based OCT system was used to measure the adherence of coronary stents.
Study: NCT05585918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEL + Equity
Description: For the SEL + Equity (experimental) condition schools, activities include those in the SEL Only condition, as well as equity lessons designed by the project team, as well as training and individualized support for implementing classroom equity lessons, five 45-minute equity professional development sessions, and one-on-one coaching to support equitable practices and the implementation of the 6 classroom equity lessons.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SEL Only
Description: For the SEL Only (active comparator) condition schools, activities involve school-wide technical assistance and implementation support for SEL curriculum implementation, as well as individualized technical assistance for the SEL curriculum. In the year following participation, SEL Only condition schools are offered access to and training and technical support for the classroom equity lessons.
Study: NCT04444843

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate Mofetil Capsules
Description: Patients who received MMF+TAC+ Corticosteroids immunosuppressive regimen as first choice post transplantation
Study: NCT04695704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: 10 mg oral montelukast once daily for 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 10 mg oral placebo once daily for 28 days
Study: NCT05701241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin analog
Description: Somatostatin analog treatment every 4 weeks
Study: NCT04692467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: Amlodipine, Haiti's first-line antihypertensive medication, will be administered to the intervention group.
Study: NCT05716022

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: Prior to subject's surgical procedure, blood (about 3 tablespoons (44 mL)) will be collected through a needle in vein for research purposes. The UVA researchers will analyze the biomarkers that are expressed in subject's blood.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: Prior to subject's surgical procedure, blood (about 3 tablespoons (44 mL)) will be collected through a needle in vein for research purposes. The UVA researchers will analyze the biomarkers that are expressed in subject's blood.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy
Description: Following blood collection, the subject will undergo the bronchoscopy for research purposes. While in the operating room, a bronchoscope will be inserted through the breathing tube that is already been placed for the surgery. Subject's airways will be examined with the bronchoscope in both lungs. Ten tablespoons (150 mL) of saline solution will be injected into one of subject airways. The fluid will be re-collected by suctioning it back up with the bronchoscope. The fluid will be collected from the bronchscope.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy
Description: Following blood collection, the subject will undergo the bronchoscopy for research purposes. While in the operating room, a bronchoscope will be inserted through the breathing tube that is already been placed for the surgery. Subject's airways will be examined with the bronchoscope in both lungs. Ten tablespoons (150 mL) of saline solution will be injected into one of subject airways. The fluid will be re-collected by suctioning it back up with the bronchoscope. The fluid will be collected from the bronchscope.
Study: NCT06258213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABP-745
Description: 0.5, 5 or 25 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT05196971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10345 84mg
Description: 6 sprays of HS-10345 84 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 sprays of placebo self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase
Study: NCT06141720

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pain education
Description: Pain education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness of pain introduction and intervention
Description: Brief mindfulness of pain introduction and intervention
Study: NCT06062524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aorta Vascular Plug System
Description: The Aorta Vascular Plug System for false lumen is composed of a vascular plug system and an adjustable bend conveyor. The plug system is composed of a patch and a conveying steel cable. The plug is pre-installed on the conveying steel cable.
Study: NCT04855045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sepofarsen
Description: RNA antisense oligonucleotide for intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sepofarsen
Description: RNA antisense oligonucleotide for intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sepofarsen
Description: RNA antisense oligonucleotide for intravitreal injection
Study: NCT05411601

Intervention type: OTHER
Intervention: Methodology of attachment of external foot prothesis
Description: establishing the methodology of specific measurements of attachment of external foot prothesis

Intervention type: OTHER
Intervention: Methodology of attachment of external foot prothesis
Description: establishing the methodology of specific measurements of attachment of external foot prothesis
Study: NCT05308849

Intervention type: OTHER
Group type: OTHER
Intervention: Dosage of serum and peritoneal of the betalactam used for antibiotic treatment
Description: All patients will have antibiotherapy according to French recommendation.~Antibiotics recommended are:~cefotaxime 200mg/kg/d / OR amoxicillin/clavulanic acid 25 mg/kg x 3 /d OR piperacilline/tazobactam 100 mg/kg/d~Blood samples will be collected before surgery and after surgery (for all patients).~Peritoneal sample will be collected during surgery (for all patients). Additionnal optionnal blood sample could be collected on Day 5 after surgery. Additionnal optionnal peritoneal samples could be collected on Day 2 and Day 5.~Dosage of serum and peritoneal of the used betalactam will be performed by High Performance Liquid Chromatography Method
Study: NCT05732077

Intervention type: DRUG
Group type: OTHER
Intervention: Dopamine
Description: A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status

Intervention type: DRUG
Group type: OTHER
Intervention: Dopamine
Description: A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fractional Flow Reserve, Renal
Description: Renal FFR will be measured based on SOP

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fractional Flow Reserve, Renal
Description: Renal FFR will be measured based on SOP

Intervention type: DEVICE
Group type: OTHER
Intervention: Renal artery stenting
Description: Renal artery stenting will be implanted based on the protocol

Intervention type: DEVICE
Group type: OTHER
Intervention: Renal artery stenting
Description: Renal artery stenting will be implanted based on the protocol
Study: NCT05979207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV367
Description: Single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P. falciparum IBSM infection
Description: Induced Blood Stage Malaria
Study: NCT04855045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sepofarsen
Description: RNA antisense oligonucleotide for intravitreal injection
Study: NCT05129332

Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal Moisturizer
Description: Natural oil-based vaginal moisturizers, like Vitamin E Oil or Coconut Oil, will be applied topically (dime-size amount) on the labia externally and vagina internally nightly, but at least 3 times per week.
Study: NCT05622643

Intervention type: OTHER
Intervention: MRI
Description: Comparison between groups

Intervention type: OTHER
Intervention: MRI
Description: Comparison between groups
Study: NCT04897035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dayspring Active Wearable Compression System
Description: Dayspring Active Wearable Compression System
Study: NCT05129332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaginal Moisturizer
Description: Natural oil-based vaginal moisturizers, like Vitamin E Oil or Coconut Oil, will be applied topically (dime-size amount) on the labia externally and vagina internally nightly, but at least 3 times per week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal Dilator
Description: Vaginal dilator will be inserted vaginally and used daily, but at least 3 times per week.